Because DNA-damage is known to stabilize and activate p53, and p53 is most often wild-type in HPV-positive cancers, we predicted that in HPV+ head and neck cancer cell lines the expression of active wild-type p53 can be promoted by cisplatin treatment. Here, TP53 is linked to cancer.